glp-1 molecule Glucagon-like peptide-1 receptor Glucagon-like peptide 1 molecule, illustration

For these and all other chronic conditions, patients, and society in general, understand that without continuous treatment, their disease will not be well controlled and lead to complication, Hurtado told Healthline

That leads to weight loss, says Supriya Rao, MD, a doctor in internal medicine, gastroenterology, obesity medicine, and lifestyle medicine in Boston

This unconscious overconsumption of food contributes to excessive weight gain

Key findings: Searches for GLP-1 side effects have increased by 4,900% since January 2023, hitting an all-time high in March 2026 Searches for dry mouth have simultaneously reached their highest ever recorded level in March 2026 moving in lockstep with GLP-1 awareness Searches for Ozempic side effects have dropped 58% since their 2024 peak, as Americans shift to searching the broader drug category a sign of growing medical literacy States with the highest GLP-1 usage show lower awareness of oral health risks a nationwide awareness gap affecting tens of millions of patients California, Texas, Florida, and New York together generated over 92,000 searches for GLP-1-related oral health symptoms in 2024 alone States like New Jersey (+36%), Massachusetts (+48%), and Rhode Island (+68%) saw explosive prescription growth in 2024 , with no equivalent rise in oral health awareness West Virginia is the most at-risk state in the country , with the highest GLP-1 usage rate (24%) and an awareness gap nearly five times worse than Hawaii, the best-performing state The ten most at-risk states are almost exclusively concentrated in the rural South and Midwest including Kentucky, Oklahoma, Louisiana, Alabama, and Arkansas Despite lower prescription rates, large states including Texas, Georgia, New Jersey, and Ohio all sit in the riskier half of the awareness gap ranking California, Texas, Florida, and New York together generated over 92,000 searches for GLP-1-related oral health symptoms in 2024 alone States like New Jersey (+36%), Massachusetts (+48%), and Rhode Island (+68%) saw explosive prescription growth in 2024 , with no equivalent rise in oral health awareness

That can look a little different for everyone, though, depending on their dietary preferences and needs

Bimagrumab : This novel monoclonal antibody blocks activin type II receptors (ActRII), primarily inhibiting myostatin